Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.
The FDA granted Priority Review to the supplemental BLA (sBLA) for efgartigimod alfa-fcab for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia ...
In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after ...
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the ...
StyleBlueprint on MSN
What the heck is NAD? (And should you be taking it?)
If you spend time in wellness circles (or on social media), you’ve probably heard rumblings about NAD, a buzzy little ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results